Angle's Maiden M&A Fills Gaps In Liquid Biopsy Solution
By acquiring Axela Inc, liquid biopsy specialist Angle PLC will now be able to pair the Canadian firm's gene expression measurement technology with its Parsortix circulating tumor cell harvesting system. Angle will finance this transaction with the proceeds it expects to raise from a proposed £12.2m share placement.
You may also be interested in...
The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in September and October 2017.
Santhera Pharmaceuticals’ vamorolone for treating Duchenne muscular dystrophy is among the latest medicines that have been submitted for review for potential pan-EU approval.